Aims: We evaluated the effect of cyclooxygenase-2 inhibitor rofecoxib added to atorvastatin, initiated immediately after percutaneous coronary angioplasty (PCI), on C-reactive protein (CRP) and interleukin-6 (IL-
NEW ISSUE
Ischaemia with non-obstructive coronary arteries, OCT vs IVUS guidance in PCI; the ILUMIEN III and ILUMIEN IV trials…
January 20, 2021